Drugs / LB03002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00596037 | Aug 2006 → Sep 2008 | pituitary deficiency, pituitary gland disorder | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00294619 | Apr 2006 → Mar 2008 | pituitary deficiency, pituitary gland disorder | LG Life Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB03002 | “A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth...” NCT00294619 ↗ |
| Modality | Protein / enzyme biologic | “a new weekly administered growth hormone preparation” NCT00294619 ↗ |
| Route | Subcutaneous | “subcutaneous injection, once-weekly” NCT00294619 ↗ |